Manufacturers

INEX Innovations Exchange Pte. Ltd.

04-21, 89 Science Park Drive, The Rutherford, Singapore Science Park , 118261 Singapore
Singapore

Telephone +65 67730698
Fax +65 68730240
vinita.c@inex.sg

This company is co-exhibitor of
Singapore Manufacturing Federation

Trade fair hall

  • Hall 3 / G74
 Interactive Plan

Hall map

MEDICA 2016 hall map (Hall 3): stand G74

Fairground map

MEDICA 2016 fairground map: Hall 3

Our range of products

Product categories

  • 03  Diagnostics
  • 03.01  Clinical chemistry
  • 03.01.07  Gene tests / molecular biological diagnostic

Gene tests / molecular biological diagnostic

  • 03  Diagnostics
  • 03.01  Clinical chemistry
  • 03.01.07  Gene tests / molecular biological diagnostic
  • 03.01.07.02  DNA analysis
  • 03  Diagnostics
  • 03.01  Clinical chemistry
  • 03.01.07  Gene tests / molecular biological diagnostic
  • 03.01.07.03  DNA sequencing
  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.08  Units and systems for the determination of immunoglobulins and plasma proteins

Units and systems for the determination of immunoglobulins and plasma proteins

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.08  Units and systems for the determination of immunoglobulins and plasma proteins
  • 03.02.08.01  Diagnostic agents / kits for immunoglobulin and plasma protein determination

Diagnostic agents / kits for immunoglobulin and plasma protein determination

Our products

Product category: Diagnostic agents / kits for immunoglobulin and plasma protein determination, Units and systems for the determination of immunoglobulins and plasma proteins

OvaCis - Rapid Colourimetric Assay

OvaCis™ is a small portable kit that distinguishes between benign and malignant ovarian cysts in five minutes. Offering 98% accuracy, doctors and patients can enjoy time and cost savings. 

Fast and accurate:
• Results in 5 minutes
• Easy-to-use surgery kit
• Allows doctor to make on-the-spot surgical decisions on further patient management
 

Reliable quality:
• Results based on sample of cyst fluid taken from patient during laparoscopic surgery
• Innovative approach using cyst fluid which is homogenous
• Ideal for medical settings with no on-site facilities for histologies

3 Simple Steps
• Obtain cyst fluid
• Apply to OvaCis™ kit
• Reagents in kit combine to give colourimetric reaction: positive (malignant cancer) or negative (benign cancer) results in 5 minutes

Who Can Use It
Healthcare professionals, e.g. clinicians, doctors and nurses, can use the kit on-site for women undergoing an ovarian cystectomy.

Why OvaCis™
OvaCis™ can be used in conjunction with laparoscopic ovarian cystectomies to offer quick detection of malignant cysts (positive results) or benign cysts (negative results).

OvaCis™ is now CE marked for in vitro diagnostic use. It has been certified to meet the EC Directive 98/79/EC for IVD products.
For distribution enquiries, please contact us at sue.chuah@inex.sg or +65 6773 0698

More Less

Product category: Gene tests / molecular biological diagnostic, DNA analysis, DNA sequencing

iGene Non Invasive Prenatal Test (NIPT)

iGene® is a revolutionary non-invasive prenatal blood test (NIPT) that can detect fetal chromosomal abnormalities such as Down Syndrome, Edward Syndrome and Patau Syndrome with more than 99%1 accuracy. iGene® is suitable for pregnant mothers who are at 10 weeks of gestation and above.

The test has drastically changed the course of prenatal screening because it offers expectant mothers accurate results without the risk of miscarriage. It is anticipated that the use of iGene® as a prenatal screening tool can reduce the rate at which invasive procedures such as amniocenteses by as much as 95%.

iGene® is based on a whole genome sequencing approach, where millions of reads from sequencing data across the genome are analysed to enhance the precision and accuracy of the test results. Unlike other tests, whole genome sequencing data has comprehensive coverage with Trisomy 21, 18 and 13, along with sex chromosome aneuploidies, certain deletion syndromes and fetal sex information.

• SAFE AND SIMPLE
Requires only 10ml of maternal blood – paternal blood is not required for the iGene® test.

• COMPREHENSIVE
Sequences data from the 23 pairs of chromosomes to accurately detect no just trisomies, but sex chromosome abnormalities and selected deletions.

• REVOLUTIONARY
Inherent biases in sequenced chromosomal data lead to read count variability. One such bias is the Guanine-Cytosine content (GC) bias; the iGene® algorithm removes GC content bias, resulting in lower error rates.

• ACCURATE
A deeper analysis based on the whole genome sequencing approach gives you more than 99% accuracy, so you can be confident of results.

• FAST
Quick turnaround time for results between 7 to 10 business days upon receipt of sample in the laboratory.

• CLEAR-CUT REPORTS
Critical information is delivered as definitive results that don’t rely on numerical risk scores.

For more information, please visit www.igeneprenataltest.com or call iGene at +65 6773 0698

More Less

Company news

Date

Topic

Download

Sep 1, 2016

IGENE WINS SINGAPORE PRESTIGE BRAND AWARD 2016

1 September 2016, Singapore, INEX INNOVATIONS EXCHANGE PTE LTD is pleased to announce that iGene has been awarded the Singapore Prestige Brand Award (SPBA) under the “SPBA – Micro Brands” category today. Vinita Choolani, Vice President of Sales and Marketing and Dr. Francisco M. Gil-Salas, Head of Business Development attended the event to receive this prestigious award.

Established in 2002 by the Association of Small and Medium Enterprises (“ASME”) and Lianhe Zaobao, SPBA recognises and honours Singapore brands that are developed and managed effectively through various branding initiatives.

Ms Vinita Choolani, Vice President of Sales and Marketing commented, “We are proud to be awarded the SPBA Award in the Micro Brands category. The iGene® brand is about giving women accurate information to make informed decisions about their pregnancy, and their baby. The win is a testament to the vision, dedication and excellence of the iGene® marketing team in conceiving and developing the brand. We are also grateful to IE Singapore for their support in providing the grant to allow us to develop our brand, and to our partner labs, distributors and vendors for their support that have helped INEX achieve this milestone.”

Dr. Francisco M. Gil-Salas, Head of Business Development, INEX commented, “We are a young made-in-Singapore company within the biotech industry, with typically little brand visibility. We wanted to change this by participating in the SPBA, to show that biotech startups can have strong brands. The recognition from SPBA would also serve as a great way to build our reputation and credibility for our innovative technology, and encourage us to strive for excellence.”

About INEX Innovations Exchange
Established in 2006, Innovations Exchange Pte Ltd (INEX) is a pioneering molecular diagnostic company focused on the research, development, marketing and licensing of innovative technology for the advancement of maternal and fetal health.

INEX started as a small molecular diagnostics company ten years ago. Today, INEX holds numerous patents and licenses in key areas serving women’s health, including OvaCisTM, an ovarian cancer IVD detection kit, iGene®, a non-invasive prenatal testing, and FlashFISHTM, which performs same-day prenatal diagnosis.

www.inex.sg.

About iGene
iGene® is a revolutionary non-invasive prenatal blood test that can detect fetal chromosomal abnormalities such as Down Syndrome with more than 99% accuracy. iGene® is suitable for pregnant mothers who are at 10 weeks of gestation and above.

The test has drastically changed the course of prenatal screening because it offers expectant mothers accurate results without the risk of miscarriage. It is anticipated that the use of iGene® as a prenatal screening tool can reduce the rate of invasive procedures such as amniocenteses by as much as 95%.

www.igeneprenataltest.com.

For more information, please contact:

Sue Voon
Senior Marketing Executive
INEX Innovations Exchange Pte Ltd
Tel: 6773 0698
Email: sue.chuah@inex.sg

More Less

Jul 20, 2016

INEX Announces Launch of World’s First CE-IVD Point-of-Care Diagnostic Assay for the Detection of Ovarian Cancer in the Operating Theatre

Singapore, July 20, 2016 - INEX Innovations Exchange Pte Ltd, a leading Women’s Health Molecular Diagnostics Services Provider in Singapore, announced today that the OvaCis™ Assay is now CE marked for in vitro diagnostic use. It has been certified to meet the EC Directive 98/79/EC for IVD products.

OvaCis™ is the world’s first Point-of-Care diagnostic assay for the detection of ovarian cancer in the operating theatre and is able to discriminate benign from malignant epithelial ovarian cysts with 98% accuracy in five minutes.

“Globally there are 240,000 ovarian cancer cases per year, with 152,000 deaths annually. Frozen section, the current mainstay of intraoperative diagnosis for epithelial ovarian cancer is not universally available. OvaCis™ can accurately detect the presence of cancer within ovarian cysts within five minutes of obtaining a sample of ovarian cyst fluid,” said Dr. Khalil Razvi, Founder of INEX Innovations Exchange.

According to Robert Hodges, Chief Operating Officer of INEX, “This is a historic milestone for Singapore’s biotech and molecular diagnostics industry. We believe OvaCis™ will revolutionise the way ovarian cysts are managed during surgery, and impact the choice of the operative surgical procedures.”

“Receiving the CE certification for our made-in-Singapore kits is a stamp of international endorsement of our innovation here in Singapore. We are in the process of manufacturing our first batch of OvaCis™ kits, which will be commercially available by Q4 this year. With the CE certification, INEX will be poised to capture the growing IVD market in Europe.”

About INEX Innovations Exchange
Established in 2006, Innovations Exchange Pte Ltd (INEX) is a pioneering molecular diagnostic company focused on the research, development, marketing and licensing of innovative technology for the advancement of women’s and fetal health. A spin out from the National University of Singapore (“NUS”), INEX collaborates with prominent clinicians, clinician-scientists and academic institutions to develop innovative technologies and revolutionise medicine for women’s healthcare. For more information about INEX, please visit www.inex.sg

About OvaCis™
OvaCis™ is an innovative colourimetric kit that accurately discriminates benign from malignant epithelial ovarian cysts with 98% accuracy, in 5 minutes. More than 90% of all ovarian malignancies are of epithelial origin, called epithelial ovarian cancer (EOC). Ovarian cysts are commonly present in most EOCs. Each year a large number of women go for ovarian cystectomy to remove ovarian cysts that are thought to benign. The intraoperative detection of malignancy for women going for ovarian cystectomy is critical for triage of patients for the most suitable surgical procedures, particularly important for young patients who wish to preserve fertility, and prevent unnecessary multiple surgeries. www.ovacis.com.sg

For more information, please contact:

Sue Voon
Senior Marketing Executive
INEX Innovations Exchange Pte Ltd
Email: sue.chuah@inex.sg
Tel: +65 6773 0698

More Less

About us

Company details

INEX Innovations Exchange 

Established in 2006, Innovations Exchange Pte Ltd (INEX) is a pioneering molecular diagnostic company focused on the research, development and marketing of innovative technology for the advancement of women’s health, including maternal and fetal health.

INEX collaborates with prominent clinical scientists and academic institutions to leverage innovative technologies and revolutionise medicine for improved and safer outcomes.

We started as a small molecular diagnostics company ten years ago. Today, INEX holds numerous patents and licenses in key areas serving women’s health, including OvaCis™, an ovarian cancer IVD detection kit, iGene®, a non invasive prenatal testing (NIPT), and FlashFISH™, which performs same-day prenatal diagnosis.

For more info, please visit www.inex.sg

More Less

Company data

Area of business
  • Electromedical equipment / Medical Technology
  • Diagnostics